LEU001 / King's College London, Leucid Bio - LARVOL DELTA

Phase I Trial: T4 Immunotherapy of Head and Neck Cancer (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: King's College London | Trial completion date: Dec 2023 ➔ Jan 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study. (PubMed, J Immunother Cancer) - P1 | "These data demonstrate the safe intratumoral administration of T4 immunotherapy in advanced HNSCC."

IO biomarker • Journal • Fatigue • Head and Neck Cancer • Oncology • Pain • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • IL4